Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Development and prospects for bispecific antibody-based therapeutics in cancer and other applications.

Lum LG, Al-Kadhimi Z.

Expert Opin Drug Discov. 2008 Sep;3(9):1081-97. doi: 10.1517/17460441.3.9.1081.

PMID:
23506181
[PubMed]
2.

Cancer therapy with bispecific antibodies: Clinical experience.

Thakur A, Lum LG.

Curr Opin Mol Ther. 2010 Jun;12(3):340-9. Review.

PMID:
20521223
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Targeting T cells with bispecific antibodies for cancer therapy.

Lum LG, Thakur A.

BioDrugs. 2011 Dec 1;25(6):365-79. doi: 10.2165/11595950-000000000-00000. Review.

PMID:
22050339
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

The new face of bispecific antibodies: targeting cancer and much more.

Lum LG, Davol PA, Lee RJ.

Exp Hematol. 2006 Jan;34(1):1-6. Review.

PMID:
16413384
[PubMed - indexed for MEDLINE]
5.

Retargeting T cells and immune effector cells with bispecific antibodies.

Lum LG, Davol PA.

Cancer Chemother Biol Response Modif. 2005;22:273-91. Review.

PMID:
16110617
[PubMed - indexed for MEDLINE]
6.

Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.

Katzenwadel A, Schleer H, Gierschner D, Wetterauer U, Elsässer-Beile U.

Anticancer Res. 2000 May-Jun;20(3A):1551-5.

PMID:
10928069
[PubMed - indexed for MEDLINE]
7.

Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.

Lum HE, Miller M, Davol PA, Grabert RC, Davis JB, Lum LG.

Anticancer Res. 2005 Jan-Feb;25(1A):43-52.

PMID:
15816517
[PubMed - indexed for MEDLINE]
Free Article
8.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
[PubMed - indexed for MEDLINE]
9.

Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.

Vincent KJ, Zurini M.

Biotechnol J. 2012 Dec;7(12):1444-50. doi: 10.1002/biot.201200250. Epub 2012 Nov 1. Review.

PMID:
23125076
[PubMed - indexed for MEDLINE]
10.

Bispecific antibodies for cancer immunotherapy: Current perspectives.

Müller D, Kontermann RE.

BioDrugs. 2010 Apr 1;24(2):89-98. doi: 10.2165/11530960-000000000-00000. Review.

PMID:
20199124
[PubMed - indexed for MEDLINE]
11.

Engineered antibodies take center stage.

Huston JS, George AJ.

Hum Antibodies. 2001;10(3-4):127-42. Review.

PMID:
11847424
[PubMed - indexed for MEDLINE]
12.

Bispecific and bifunctional single chain recombinant antibodies.

Kriangkum J, Xu B, Nagata LP, Fulton RE, Suresh MR.

Biomol Eng. 2001 Sep;18(2):31-40. Review.

PMID:
11535414
[PubMed - indexed for MEDLINE]
13.

Recombinant bispecific antibodies for cellular cancer immunotherapy.

Müller D, Kontermann RE.

Curr Opin Mol Ther. 2007 Aug;9(4):319-26. Review.

PMID:
17694444
[PubMed - indexed for MEDLINE]
14.

Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors.

Patrick TA, Kranz DM, Zachary JF, Roy EJ.

Int J Cancer. 1998 Nov 9;78(4):470-9.

PMID:
9797136
[PubMed - indexed for MEDLINE]
15.

Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.

Gu J, Ghayur T.

Methods Enzymol. 2012;502:25-41. doi: 10.1016/B978-0-12-416039-2.00002-1.

PMID:
22208980
[PubMed - indexed for MEDLINE]
16.

Current perspectives of bispecific antibody-based immunotherapy.

Talac R, Nelson H.

J Biol Regul Homeost Agents. 2000 Jul-Sep;14(3):175-81. Review.

PMID:
11037049
[PubMed - indexed for MEDLINE]
17.

Recombinant immunotoxins in targeted cancer cell therapy.

Reiter Y.

Adv Cancer Res. 2001;81:93-124. Review.

PMID:
11430597
[PubMed - indexed for MEDLINE]
18.

IBC's 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of The Antibody Society: December 2-6, 2012, San Diego, CA.

Marquardt J, Begent RH, Chester K, Huston JS, Bradbury A, Scott JK, Thorpe PE, Veldman T, Reichert JM, Weiner LM.

MAbs. 2012 Nov-Dec;4(6):648-52. doi: 10.4161/mabs.22221. Epub 2012 Sep 24.

PMID:
23007482
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.

Choi BD, Gedeon PC, Kuan CT, Sanchez-Perez L, Archer GE, Bigner DD, Sampson JH.

J Immunol Methods. 2013 Sep 30;395(1-2):14-20. doi: 10.1016/j.jim.2013.06.003. Epub 2013 Jun 24.

PMID:
23806556
[PubMed - indexed for MEDLINE]
20.

World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA.

Dhimolea E, Reichert JM.

MAbs. 2012 Jan-Feb;4(1):4-13. doi: 10.4161/mabs.4.1.18821.

PMID:
22327426
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk